Clin2
NCT06212388Possibly a fitNot yet recruiting

Immune cell therapy with interferon or PD-1 for melanoma

Melanoma

Treatments studied

Part of Cancer, Skin clinical trials.

This trial tests a special type of immune cells (gamma-delta T cells) given with either interferon or a PD-1 inhibitor for people with stage III-IV melanoma that can be removed with surgery. The goal is to see if this combination helps the immune system fight the cancer and prevent it from coming back.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
10 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have stage III or IV melanoma that can be removed by surgery (not uveal melanoma).
  • You are generally healthy enough to get around (ECOG score 0 or 1).
  • You have not had other cancer treatments within the last 4 weeks (except for melanoma surgery).
  • You do not have active autoimmune disease, serious infections, or other major health issues.
  • You are not pregnant and agree to use contraception during the trial and for 1 year after.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05539118Not yet recruiting· Phase 1/Phase 2
Combination therapy for advanced melanoma

This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.

Xi'an, Shaanxi
NCT02621021Recruiting· Phase 2
Immune cell therapy for advanced melanoma

This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.

Bethesda, Maryland
NCT06204991Recruiting· Phase 1
T-cell therapy for advanced melanoma

This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.

Herlev
NCT07028008Not yet recruiting
Personalized immune cell therapy for advanced melanoma

This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.

NCT02498756Not yet recruiting· Phase 2
Immune cell therapy for advanced melanoma

This trial tests a type of immune cell therapy called cytokine-induced killer cells for people with advanced melanoma that has not responded to other treatments. It aims to see if these cells can help shrink or slow down the cancer.

NCT06739226Not yet recruiting· Phase 1/Phase 2
Combination immunotherapy for advanced melanoma

This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.

Shenzhen, Guangdong

Hear when a new Melanoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.